[1] [1] RUZE R, LIU T T, ZOU X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments[J]. Front Endocrinol (Lausanne), 2023, 14: 1161521.

[2] [2] LINGVAY I, SUMITHRAN P, COHEN R V, et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation[J]. Lancet, 2022, 399(10322): 394-405.

[3] [3] PREVENTIVE SERVICES TASK FORCE U S, KRIST A H, DAVIDSON K W, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: us preventive services task force recommendation statement[J]. JAMA, 2020, 324(20): 2069-2075.

[4] [4] MAJETY P, LOZADA ORQUERA F A, EDEM D, et al. Pharmacological approaches to the prevention of type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2023, 14: 1118848.

[5] [5] SANDOVAL D A, PATTI M E. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia[J]. Nat Rev Endocrinol, 2023, 19(3): 164-176.

[6] [6] COURCOULAS A P, GALLAGHER J W, NEIBERG R H, et al. Bariatric surgeryvslifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial[J]. J Clin Endocrinol Metab, 2020, 105(3): 866-876.

[7] [7] ELGENAIED I, EL ANSARI W, ELSHERIF M A, et al. Factors associated with complete and partial remission, improvement, or unchanged diabetes status of obese adults 1 year after sleeve gastrectomy[J]. Surg Obes Relat Dis, 2020, 16(10): 1521-1530.

[8] [8] TU Y F, WANG L, WEI L, et al. Cost-utility of laparoscopic roux-en-Y gastric bypass in Chinese patients with type 2 diabetes and obesity with a BMI≥27.5 kg/m2: a multi-center study with a 4-year follow-up of surgical cohort[J]. Obes Surg, 2019, 29(12): 3978-3986.

[9] [9] KAPELUTO J E, TCHERNOF A, MASCKAUCHAN D, et al. Ten-year remission rates in insulin-treated type 2 diabetes after biliopancreatic diversion with duodenal switch[J]. Surg Obes Relat Dis, 2020, 16(11): 1701-1712.

[10] [10] ROHDE U, HEDBCK N, GLUUD L L, et al. Effect of the endo barrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2016, 18(3): 300-305.

[11] [11] SINGH A, NISSEN S E. Contemporary management of obesity: a comparison of bariatric metabolic surgery and novel incretin mimetic drugs[J]. Diabetes Technol Ther, 2024, 26(9): 673-685.

[12] [12] ALLAM-NDOUL B, CASTONGUAY-PARADIS S, VEILLEUX A. Gut microbiota and intestinal trans-epithelial permeability[J]. Int J Mol Sci, 2020, 21(17): 6402.

[13] [13] RAJAGOPALAN H, CHERRINGTON A D, THOMPSON CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study[J]. Diabetes Care, 2016, 39(12): 2254-2261.

[14] [14] VARGAS E J, RIZK M, BAZERBACHI F, et al. Medical devices for obesity treatment: endoscopic bariatric therapies[J]. Med Clin North Am, 2018, 102(1): 149-163.

[15] [15] CHERRINGTON A D, RAJAGOPALAN H, MAGGS D, et al. Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease[J]. Gastrointest Endosc Clin N Am, 2017, 27(2): 299-311.

[16] [16] VAN BAAR A C G, BEUERS U, WONG K, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results[J]. JHEP Rep, 2019, 1(6): 429-437.

[17] [17] CAO Y, REN G F, ZHANG Y H, et al. A new way for punicalagin to alleviate insulin resistance: regulating gut microbiota and autophagy[J]. Food Nutr Res, 2021, 65: 65.

[18] [18] GONZALEZ L M, MOESER A J, BLIKSLAGER A T. Porcine models of digestive disease: the future of large animal translational research[J]. Transl Res, 2015, 166(1): 12-27.

[19] [19] HAIDRY R J, VAN BAAR A C, GALVAO NETO M P, et al. Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting[J]. Gastrointest Endosc, 2019, 90(4): 673-681. e2.

[20] [20] VAN BAAR A C G, DEVIRE J, HOPKINS D, et al. Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)[J]. Diabetes Res Clin Pract, 2022, 184: 109194.

[21] [21] MINGRONE G, VAN BAAR A C, DEVIRE J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial[J]. Gut, 2022, 71(2): 254-264.

[22] [22] HOYT J A, COZZI E, D'ALESSIO D A, et al. A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes[J]. Diabetes Obes Metab, 2024, 26(6): 2017-2028.

[23] [23] DUCA F A, ZAVED WAISE T M, PEPPLER W T, et al. The metabolic impact of small intestinal nutrient sensing[J]. Nat Commun, 2021, 12(1): 903.

[24] [24] POSTLER T S, GHOSH S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system[J]. Cell Metab, 2017, 26(1): 110-130.

[25] [25] SANNA S, VAN ZUYDAM N R, MAHAJAN A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases[J]. Nat Genet, 2019, 51(4): 600-605.

[26] [26] LI Q, CHEN H X, ZHANG M, et al. Altered short chain fatty acid profiles induced by dietary fiber intervention regulate AMPK levels and intestinal homeostasis[J]. Food Funct, 2019, 10(11): 7174-7187.

[27] [27] MISHRA A K, DUBEY V, GHOSH A R. Obesity: an overview of possible role(s) of gut hormones, lipid sensing and gut microbiota[J]. Metabolism, 2016, 65(1): 48-65.

[28] [28] SMITH K R, MORAN T H. Gastrointestinal peptides in eating-related disorders[J]. Physiol Behav, 2021, 238: 113456.

[29] [29] HONG S H, CHOI K M. Gut hormones and appetite regulation[J]. Curr Opin Endocrinol Diabetes Obes, 2024, 31(3): 115-121.

[30] [30] ZHAO S F, YAN Z M, DU Y, et al. A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes[J]. Br J Pharmacol, 2022, 179(17): 4360-4377.

[31] [31] YAN Y Q, WU T T, ZHANG M, et al. Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population[J]. BMC Public Health, 2022, 22(1): 1382.

[32] [32] RUZE R, XU Q, LIU G Q, et al. Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats[J]. Am J Physiol Endocrinol Metab, 2021, 321(3): E392-E409.

[33] [33] FEI Z, XU Y, ZHANG G Y, et al. Natural products with potential hypoglycemic activity in T2DM: 2019—2023[J]. Phytochemistry, 2024, 223: 114130.

[34] [34] JIANG B, WANG H J, LI N, et al. Role of proximal intestinal glucose sensing and metabolism in the blood glucose control in type 2 diabetic rats after duodenal jejunal bypass surgery[J]. Obes Surg, 2022, 32(4): 1119-1129.

[35] [35] MEIRING S, BUSCH C E, VAN BAAR A G, et al. Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events[J]. Cardiovasc Diabetol, 2022, 21(1): 191.

[36] [36] MUSSO G, PINACH S, SABA F, et al. Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: a systematic review[J]. Med, 2024, 5(7): 735-758. e2.

[37] [37] LIN X H, LI H. Obesity: epidemiology, pathophysiology, and therapeutics[J]. Front Endocrinol (Lausanne), 2021, 12: 706978.

[38] [38] HADEFI A, VERSET L, PEZZULLO M, et al. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study[J]. Endosc Int Open, 2021, 9(11): E1792-E1800.

[39] [39] BUSCH C B E, MEIRING S, VAN BAAR A C G, et al. Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study[J]. Gastrointest Endosc, 2024, 100(3): 473-480.e1.

[40] [40] VAN BAAR A C G, HOLLEMAN F, CRENIER L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study[J]. Gut, 2020, 69(2): 295-303.

[41] [41] YOUNOSSI Z M, GOLABI P, DE AVILA L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.

[42] [42] FAN H, LIU Z Q, ZHANG P Y, et al. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis[J]. Hepatol Int, 2023, 17(3): 615-625.

[43] [43] HUANG D Q, EL-SERAG H B, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.

[44] [44] CHUANG T J, KO C W, SHIU S I. The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease[J]. Medicine (Baltimore), 2023, 102(40): e35147.

[45] [45] MA X Y, ZHU Y X, YEO Y H, et al. The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes[J]. Hepatol Int, 2024, 18(3): 952-963.

[46] [46] SANYAL A J, MUNOZ B, CUSI K, et al. Validation of a clinical risk-based classification system in a large nonalcoholic fatty liver disease real-world cohort[J]. Clin Gastroenterol Hepatol, 2023, 21(11): 2889-2900. e10.

[47] [47] KULKARNI S, GUPTA K, RATRE P, et al. Polycystic ovary syndrome: Current scenario and future insights[J]. Drug Discov Today, 2023, 28(12): 103821.

[48] [48] WANG J X, YIN T L, LIU S. Dysregulation of immune response in PCOS organ system[J]. Front Immunol, 2023, 14: 1169232.

[49] [49] KAUR V, DIMITRIADIS G K, PREZ-PEVIDA B, et al. Mechanisms of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovary syndrome[J]. Metabolism, 2021, 125: 154908.

[50] [50] HADEFI A, HUBERTY V, LEMMERS A, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes[J]. Dig Dis, 2018, 36(4): 322-324.

[52] [52] MEIRING S, MEESSEN E C E, VAN BAAR A C G, et al. Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes[J]. Am J Physiol Endocrinol Metab, 2022, 322(2): E132-E140.